Psilera Appoints Neuroscience Veteran Allyson Gage as VP of Clinical Development

Psilera Inc. has appointed Allyson Gage, PhD, a veteran in neuroscience, as its Vice President of Clinical Development. Gage will oversee the company's initial Phase 1 clinical trial, focusing on its lead neuroplastogen compound, PSIL-006.

Gage's appointment bolsters Psilera's operational leadership as the company advances toward clinical-stage evaluation. Psilera is developing next-generation neuroplastogens, compounds designed to promote nerve cell regeneration and brain plasticity.

The upcoming Phase 1 trial represents a critical step in assessing the safety and tolerability of PSIL-006 in humans. The results from this study will inform further development and potential future clinical investigations.

Psilera has not released specific details regarding the trial's timeline or precise objectives.